<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998334</url>
  </required_header>
  <id_info>
    <org_study_id>SAP BUNDLE-CRRT</org_study_id>
    <secondary_id>12411950500</secondary_id>
    <nct_id>NCT01998334</nct_id>
  </id_info>
  <brief_title>Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis</brief_title>
  <official_title>Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <authority>China: Science and Technology Commission of Shanghai Municipality</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic Inflammatory response syndrome(SIRS) is common in patients with severe acute
      pancreatitis (SAP) in early stage. Continuous Blood Purification (CBP), especially
      Continuous Veno-Venous Hemofiltration(CVVH) is proved to have an important role in SAP
      patients to control SIRS. But the detail treatment for this is controversial. In this study,
      the investigators aim to evaluate the different effects of three kinds of treatment
      protocols which is CVVH 6h,continuous venovenous hemodiafiltration(CVVHDF) 6h,CVVH 10h for
      first three days in SAP patients. Compare the vital sign, SIRS parameters, and others
      between these three groups. This study will try to find a better way for CBP in patients
      with SAP
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Condition Severe Acute Pancreatitis

      Intervention CVVH 6 hours for first three days CVVH 10 hours for first three days CVVHDF 6
      hours for first three days

      All therapeutic volume is 45ml/kg.h, Device: Braxter HF 1200
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Efficiency of CBP with Inflammatory Response</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Efficiency of CBP with inflammatory response was assessed by the following measurements:
Inflammatory mediators removal:tumor necrosis factor-α, interleukin(IL-1, IL-2, IL-6, and IL-8, IL-10, sIL-2R)before and after CBP in first three days
SIRS parameters variation: (Heart rate, respiratory rate, White Blood Cell, Temperature, C response protein) before and after CBP in first three days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality of 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>operation time of 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local complication of severe acute pancreatitis</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>local complication of SAP in 28 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ICU and hospital duration</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>CVVH 6h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVVH 6h for first three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVVH 10h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVVH 10h for first three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVVHDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CVVHDF 6h for first three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CVVH 6h</intervention_name>
    <description>CVVH 6h for first three days</description>
    <arm_group_label>CVVH 6h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CVVH 10h</intervention_name>
    <description>CVVH 10h for first three days</description>
    <arm_group_label>CVVH 10h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CVVHDF 6h</intervention_name>
    <description>CVVHDF 6h for first three days</description>
    <arm_group_label>CVVHDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria:

          1. Diagnosis of pancreatitis:

               -  Typical pain

               -  Increase in serum lipase or amylase

               -  Onset of abdominal pain within &lt;=72h before admission

          2. The diagnosis criteria of Severe Acute Pancreatitis is according to Atlanta criteria
             revisited in 2012

          3. no chronic diseases such as Chronic Obstructive Pulmonary Disease, Diabetes Mellitus
             and so on

          4. Age from 18 to 65 years old

        Besides criteria above, the patient should also satisfied one of these CBP criteria:

          1. Have Acute Kidney Injury satisfied RIFLE classification (risk above): increased Serum
             Creatinine &gt; 1.5 times baseline，26.5umol/L increase, or urine output &lt; 0.5ml/kg.h for
             6 hours

          2. Systemic Inflammatory Response Syndrome: temperature &gt;38℃ or&lt;36℃；heart rate
             respiratory rate White blood cell count &gt;12*10^9/L，or&lt; 4*10^9/L

          3. Refractory acid-base and electrocyte balance disorder, metabolic acidosis
             conservative treatment is not effective.

        Exclusion Criteria:

          1. Pregnancy

          2. Chronic pancreatitis

          3. Immunosuppression condition such as HIV, Corticosteroid  for 3 weeks in 60 days;
             White Blood Cell &lt; 0.5*10^9/L for 10 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enqiang Mao, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Department of EICU  Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of EICU, Ruijin Hospital,</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erzhen Chen, M.D</last_name>
      <phone>86-13901753478</phone>
    </contact>
    <contact_backup>
      <last_name>Enqiang Mao, M.D</last_name>
      <phone>13501747906</phone>
    </contact_backup>
    <investigator>
      <last_name>Jingyi Wu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erzhen Chen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 23, 2013</lastchanged_date>
  <firstreceived_date>November 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Erzhen Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Systemic Inflammatory Response Syndrome</keyword>
  <keyword>Continuous Blood Purification</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
